FindTrial
Sign In

Treatment With Crizotinib Single Patient Expanded Access IND 134375

Treatment With Crizotinib Single Patient Expanded Access IND 134375

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT03085186
Enrollment
Unknown
Registered
2017-03-21
Start date
Unknown
Completion date
Unknown
Last updated
2017-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Myofibroblastic Tumour

Brief summary

Two year old male with a new diagnosis of Inflammatory Myofibroblastic Tumour. The patient presented with 2 months of intermittent fever and 1-2 weeks of abdominal distention and constipation. An abdominal mass was palpable on exam and US concerning was for neoplasm of abdomen. Treatment with Crizotinib will be utilized to reduce the size of the lesion and create more optimal tissue plains between vital structures prior to attempted surgical resection would greatly reduce potential morbidity for this patient.

Interventions

DRUGCrizotinib

Sponsors

Pfizer
CollaboratorINDUSTRY
Jean M. Tersak, M.D.
Lead SponsorOTHER

Eligibility

Sex/Gender
MALE
Age
2 Years to 2 Years

Inclusion criteria

* This treatment plan is intended for the use of Crizotinib in the treatment of a single patient with Inflammatory Myofibroblastic Tumour

Exclusion criteria

* Not applicable as Expanded Access only includes one patient

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026